Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025;9(3):207-213.

Stereotactic body radiotherapy for unresectable or locally recurrent pancreatic cancer: A single centre experience

Draghini Lorena  1 , Tebala Giovanni Domenico  2 , Casale Michelina  1 , Marzo Alessandro Di  1 , Desiderio Jacopo  1 , Trippa Fabio  1
Affiliations
  • PMID: 40476277
  • PMCID: PMC12136683 (available on )

Stereotactic body radiotherapy for unresectable or locally recurrent pancreatic cancer: A single centre experience

Draghini Lorena et al. J Radiosurg SBRT. 2025.

Abstract

Purpose: To refer our experience with stereotactic body radiotherapy (SBRT) in patients with pancreatic cancer.

Materials and methods: 45 Patients with unresectable or locally recurrent pancreatic cancer after primary surgery, were submitted to SBRT. Toxicities were graded according to CTCAE version 5. Statistical analysis was performed by the Kaplan-Meier method.

Results: The characteristics of the patients were median age 70 years (range, 46-84 years), median KPS 90% (range, 80-90%). Six patients had recurrent cancer after surgery, the other 39 patients were unresectable. Median radiation dose was 35 Gy (range, 27-40 Gy) delivered in 5 fractions. Simultaneous integrated boost with median dose of 35 Gy (range, 30-45 Gy) was given in 7 patients.After median follow-up of 10 months (range, 3-61 months) median local control was 10 months (range,5-15 months) and 49% (±8%) at 1-year. Median overall survival (OS) was 10 months (range,7-14 months), 38 % (±7%) at 1 year. Type of radiological response statistically significant influenced LC and OS, stage only LC in non-significant way. Clinical response was obtained in 12 of 36 (33%) cases. Median Numeric Rating Scale (NRS) was 7 (range, 4-8) before radiotherapy and 1 (range, 0-5) post SBRT. Acute G1-2 gastrointestinal toxicities were registered in 15% of patients, no late toxicities were found.

Conclusion: In our series we obtained a good local palliation with SBRT that is a safe and effective treatment option. Higher doses could be administered in selected patients to obtain better response to treatment that is correlated with LC and OS.

Keywords: SBRT; locally recurrent cancer; pancreatic cancer; radiosurgery; stereotactic body radiotherapy; unresectable cancer.

PubMed Disclaimer

Conflict of interest statement

Authors’ disclosure of potential conflicts of interest The authors have nothing to disclose.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics CA Cancer J Clin 2015. 65 (1): 5–29 - PubMed
    1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer Lancet 2004. 363 (9414): 1049–1057 - PubMed
    1. Panje C, Andratschke N, Brunner TB, Niyazi M, Guckemberger M. Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer literature review and practical recommendations of the DEGRO working group on stereotactic radiotherapy Strahlenther Onkol 2016. 192 (12): 875–885 - PubMed
    1. Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer Int J Radiat Oncol Biol Phys 2007. 68 (3): 801–808 - PubMed
    1. Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, Sauer O. Deutschen Gesellschaft für Radioonkologie (DEGRO) Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer Strahlenther Onkol 2014. 190 (1): 26–33 - PMC - PubMed